IBIO · Ibio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $400.0K | $225.0K | $0 | $2.38M | $2.37M | $1.64M |
| Cost of Revenue | - | - | - | $216.0K | $703.0K | - |
| Gross Profit | - | - | - | $2.17M | $935.0K | - |
| R&D | $8.31M | $5.18M | $10.33M | $17.73M | $9.99M | $3.21M |
| SG&A | $10.69M | $11.67M | $19.02M | $34.13M | $22.03M | $12.43M |
| Total Operating Expenses | $19.00M | $16.86M | $29.34M | $51.86M | $32.02M | $15.64M |
| D&A | $484.0K | $638.0K | $674.0K | $2.27M | $472.0K | $282.0K |
| Operating Income | ($18.60M) | ($16.63M) | ($29.34M) | ($49.69M) | ($31.11M) | ($14.00M) |
| Interest Expense | $212.0K | $172.0K | $83.0K | $1.41M | $2.45M | $2.47M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($18.38M) | ($24.91M) | ($29.31M) | ($50.30M) | ($23.21M) | ($16.44M) |
| EPS - Basic | ($1.75) | ($6.50) | ($106.20) | ($60.00) | - | - |
| EPS - Diluted | ($1.75) | ($6.50) | ($106.20) | ($60.00) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.58M | $14.21M | $4.30M | $22.68M | $77.40M | $55.11M |
| Accounts Receivable | - | - | - | $1.00M | $426.0K | $75.0K |
| Inventory | - | $0 | - | $3.90M | - | - |
| Accounts Payable | $2.19M | $358.0K | $1.85M | $4.26M | $2.25M | $1.76M |
| Current Assets | $9.72M | $15.67M | $26.26M | $45.07M | $104.60M | $61.75M |
| Total Assets | $23.18M | $28.73M | $41.21M | $99.41M | $146.97M | $94.19M |
| Current Liabilities | $6.11M | $3.84M | $21.58M | $30.44M | $6.64M | $5.24M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $8.30M | $7.41M | $25.83M | $35.92M | $38.40M | $37.58M |
| Stockholders' Equity | $14.88M | $21.32M | $15.38M | $63.48M | $108.58M | $56.62M |
| Retained Earnings | ($332.22M) | ($313.85M) | ($288.94M) | ($223.93M) | ($173.63M) | ($150.42M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($15.30M) | ($18.55M) | ($30.44M) | ($37.48M) | ($30.06M) | ($13.35M) |
| Investing Cash Flow | $742.0K | $906.0K | $7.01M | ($5.13M) | ($26.48M) | ($1.15M) |
| Financing Cash Flow | $8.93M | $24.49M | $2.30M | ($6.13M) | $78.83M | $65.19M |
| CapEx | $16.0K | $210.0K | $5.74M | $7.33M | $4.92M | $1.08M |
| Free Cash Flow | ($15.32M) | ($18.76M) | ($36.17M) | ($44.81M) | ($34.98M) | ($14.42M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | 90.9% | 39.4% | - |
| Operating margin | -4650.5% | -7392.9% | - | -2085.2% | -1312.1% | -854.9% |
| EBITDA margin | -4529.5% | -7109.3% | - | -1989.7% | -1292.2% | -837.7% |
| Net margin | -4594.3% | -11069.8% | - | -2110.9% | -978.8% | -1003.6% |
| Free cash flow margin | -3830.0% | -8339.6% | - | -1880.4% | -1475.5% | -880.5% |
| FCF / Net income | 0.83 | 0.75 | 1.23 | 0.89 | 1.51 | 0.88 |
| R&D / Revenue | 2078.0% | 2304.4% | - | 744.0% | 421.3% | 196.2% |
| SG&A / Revenue | 2672.5% | 5188.4% | - | 1432.1% | 929.2% | 758.7% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -79.3% | -86.7% | -71.1% | -50.6% | -15.8% | -17.5% |
| Return on equity | -123.5% | -116.8% | -190.6% | -79.2% | -21.4% | -29.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.59 | 4.08 | 1.22 | 1.48 | 15.74 | 11.79 |
| Quick ratio | 1.59 | 4.08 | 1.22 | 1.35 | 15.74 | 11.79 |
| Cash ratio | 1.41 | 3.70 | 0.20 | 0.75 | 11.65 | 10.53 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -87.7x | -96.7x | -353.5x | -35.2x | -12.7x | -5.7x |
| Equity multiplier | 1.56 | 1.35 | 2.68 | 1.57 | 1.35 | 1.66 |
| Liabilities / Assets | 0.36 | 0.26 | 0.63 | 0.36 | 0.26 | 0.40 |
| Efficiency | ||||||
| Asset turnover | 0.02 | 0.01 | 0.00 | 0.02 | 0.02 | 0.02 |
| Inventory turnover | - | - | - | 0.06 | - | - |
| Days sales outstanding | - | - | - | 153d | 66d | 17d |
| Days inventory outstanding | - | - | - | 6590d | - | - |
| Days payable outstanding | - | - | - | 7205d | 1170d | - |
| Cash conversion cycle | - | - | - | -462d | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.5x | 0.4x | 9.7x | 16.0x | - | - |
| P / S | 19.9x | 35.9x | - | 426.9x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 77.8% | - | -100.0% | 0.5% | 44.7% | -18.8% |
| Revenue CAGR (3y) | -44.8% | -54.4% | - | 5.7% | 81.9% | 60.8% |
| Revenue CAGR (5y) | -24.6% | -35.5% | - | 43.3% | 20.1% | -2.4% |
| Gross profit growth (YoY) | - | - | - | 131.8% | - | - |
| Operating income growth (YoY) | -11.8% | 43.3% | 40.9% | -59.7% | -122.2% | 11.3% |
| Net income growth (YoY) | 26.2% | 15.0% | 41.7% | -116.8% | -41.2% | 6.6% |
| EPS growth (YoY) | 73.1% | 93.9% | -77.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 18.4% | 48.1% | 19.3% | -28.1% | -142.6% | 3.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -30.2% | 38.6% | -75.8% | -41.5% | 91.8% | 2198.7% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-13.75
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing iBio against the 5 most active filers in the same SIC group.